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Abstract
OBJECTIVES: The Sutureless and Rapid-Deployment Aortic Valve Replacement International Registry (SURD-IR) was established by a con-
sortium of 18 research centres—the International Valvular Surgery Study Group (IVSSG)—to overcome limitations of the literature and pro-
vide adequately powered evidence on sutureless and rapid-deployment aortic valves replacement (SURD-AVR).
METHODS: Data from 3343 patients undergoing SURD-AVR over a 10-year period (2007–2017) were collected in the registry. The mean
age of the patients was 76.8 ± 6.7 years, with 36.4% being 80 years or older. The average logistic EuroSCORE was 11.3 ± 9.7%.
RESULTS: Isolated SURD-AVR was performed in 70.7% (n = 2362) of patients using full sternotomy (35.3%) or less invasive approaches
(64.8%). Overall hospital mortality was 2.1%, being 1.4% in patients who had isolated SURD-AVR and 3.5% in those who had concomitant
procedures (P < 0.001). When considering baseline risk profile, mortality rate was 0.8% and 1.9% in low risk (logistic EuroSCORE <10%) iso-
lated SURD-AVR and combined SURD-AVR, respectively, and 2.2% and 3.7% in higher risk patients (logistic EuroSCORE >_10%).
Postoperative neurological complications included stroke (2.8%) and transient ischaemic attack (1.1%). New atrioventricular block requir-
ing pacemaker occurred in 10.4% of the patients. The rate of pacemaker implantation significantly decreased over time [from 17.2%
(2007–2008) to 5.4% (2016); P = 0.02].
CONCLUSIONS: Our findings showed that SURD-AVR is a safe and effective alternative to conventional aortic valve replacement and is
associated with excellent clinical outcomes. Further adequately powered statistical analyses from the retrospective and prospective SURD-
IR will allow for the development of high-quality evidence-based clinical guidelines for SURD-AVR.
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INTRODUCTION
The sutureless concept of aortic valve implantation was developed
in the early 60s. However, this approach was abandoned due to
frequent valve-related thromboembolic complications and severe
paravalvular leakage [1]. More recently, new sutureless, rapid-
deployment aortic valve prostheses have been reintroduced based
on modern experience with transcatheter aortic valve implantation
(TAVI) and with the advent of bovine pericardial material for tissue
valves. However, because of the limited number of cases and the
short observational interval, the current literature on sutureless and
rapid-deployment aortic valve replacement (SURD-AVR) is still
scarce because the majority of the publications are retrospective
and based on observational nature. In addition, heterogeneous def-
initions of clinical variables, insufficient reporting of postoperative
outcomes and lack of robust follow-up data make the actual know-
ledge weak. To overcome these limitations and provide convincing
evidence for SURD-AVR surgery, the Sutureless and Rapid-
Deployment Aortic Valve Replacement International Registry
(SURD-IR) was established by a consortium of 18 research centres—
the International Valvular Surgery Study Group (IVSSG)—with the
aim to evaluate the current management and outcomes of valvular
surgery [2].
In this article, we report characteristics and hospital outcomes
of the patients enrolled in the SURD-AVR Registry.
METHODS
Sutureless and Rapid-Deployment Aortic Valve
Replacement International Registry
The Sutureless and Rapid-Deployment Aortic Valve Replacement
International Registry was established in 2015 enrolling patients
at 18 large referral centres in Europe, Australia and Canada
(Supplementary Material, Fig. S1).
The study population was defined as patients undergoing
SURD-AVR intervention using any available sutureless and rapid-
deployment valve prosthesis either by conventional sternotomy
or less invasive approach. Valve prosthesis types included
Perceval S (Livanova PLC, London, UK) EDWARDS INTUITY/
INTUITY Elite (Edwards Lifesciences, Irvine, CA, USA) and Enable
3F (Medtronic, MN, USA). Less invasive approaches involved
ministernotomy and minithoracotomy.
Details of the site selection and invitation have been previously
published [2]. Briefly, centres that had published reports on more
than 50 SURD-AVR cases were initially invited to participate in
the present database, as this was hypothesized to represent expe-
rienced centres with quality data collection. Further institutions
recommended by the IVSSG Research Steering Committee were
also invited to participate in the retrospective registry. Ethics ap-
proval was obtained at each of the participating centres, and
datasets were submitted according to predefined spreadsheet
format. Participating SURD-IR centres enrolled between 40 and
735 patients and collected information on demographics, patient
comorbidities, functional status, imaging studies, surgical data,
postoperative course, clinical and haemodynamic outcomes.
Following electronic data submission, each dataset was evaluated
to ensure that all patients were older than 18 years. All variables
between datasets were assessed with identical variables collated
into a centralized database. Isolated variables reported by less
than 25% of centres were excluded from analysis. Individually
missing data and centre-specific non-reported data were coded
separately. Clinically important absent data were queried with
the submitting centre. Data were analysed for clinical face validity
and internal validity. Submitted clinical data were compared
against published data for inconsistencies.
End points
More than 190 variables were collected for each patient.
Variables of interest for the SURD-IR involved (i) ‘clinical data’
including age, sex, New York Heart Association (NYHA) class,
CCS class, comorbidities, indications for surgery, baseline echo-
cardiographic and haemodynamic data and patient history; (ii)
‘risk assessment variables’ including logistic EuroSCORE,
EuroSCORE II, STS PROM risk and major organ system com-
promises; (iii) ‘operative details’ including surgical approach (full
sternotomy, ministernotomy or minithoracotomy), concomitant
procedures, type of prostheses, prostheses size, operative times
[cardiopulmonary bypass (CPB) duration, cross-clamp time]; (iv)
‘technical outcomes’ including immediate procedural success
(defined as successful first implant of the valve not requiring re-
peated cross-clamping), occurrence of first implant failure, valve
migration/embolization, conversion to sutured aortic valve re-
placement (AVR), postimplantation aortic valve regurgitation,
pressure valve gradients and (v) ‘hospital outcomes’ including
mortality and cause of death, echocardiography and haemo-
dynamic parameters, perioperative blood transfusion, postopera-
tive complications (cardiac, renal, respiratory, neurological,
infective, gastrointestinal and wound complications), cardiac and
aortic valve reinterventions and duration of intensive care unit
(ICU) and hospital stay. The definitions of the main variables are
described in the Supplementary material, Appendix.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation
and categorical variables as percentages. Where continuous vari-
ables did not follow a normal distribution (tested using the
Kolmogorov–Smirnov test for normality and Q–Q plots), the me-
dian and interquartile range were reported. Percentages were
calculated with the available data as the denominator.
Categorical variables were compared using the v2 test.
Normally distributed continuous data were compared using the
unpaired t-test or 1-way analysis of variance as appropriate. The
linear-by-linear association was used to evaluate linear trends
across time groups. No imputation techniques were performed
in this analysis as this is an explorative study. No formal adjust-
ments were made for the multiple tests of significance. The level
of significance, a, was set at 5% for this study.
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RESULTS
Patient demographics and risk profile
A total of 3343 patients undergoing SURD-AVR over a 10-year
period between 2007 and 2017 were enrolled in the registry. The
mean age was 76.8 ± 6.7 (range 25–94) years, with 36.4% being
80 years or older. Overall, 1371 of 3338 (41.1%) of cases were
men and more than 50% of patients presented with advanced
NYHA class symptoms (NYHA III 1540 of 3072, 50.1%; NYHA IV
169 of 3072, 5.5%). The indications for SURD-AVR were degen-
erative aortic stenosis in 2233 (66.8%) patients, aortic regurgita-
tion in 36 (1.1%) patients and mixed aortic valve pathology
(stenosis + regurgitation) in 1074 (32.1%) patients . Twenty-one of
2680 (0.8%) patients presented with active aortic valve endocar-
ditis and 115 of 2020 (5.7%) presented with a bicuspid aortic
valve. Three hundred and seventy-two (11.1%) patients had prior
cardiac surgery [coronary artery bypass grafting (CABG) n = 38,
1.1%; AVR n = 136, 4.1%]. Demographics and baseline characteris-
tics are listed in Table 1. Echocardiographic data revealed a
reduced left ventricular function [left ventricular ejection fraction
(LVEF) < 50%] in 652 of 3123 (20.9%) patients; mean aortic valve
area was 0.76 cm2 with peak and mean aortic valve gradient of
73.9 mmHg and 46.3 mmHg, respectively (Table 2).
The average logistic EuroSCORE of the study cohort was
11.3 ± 9.7%. When stratified by risk profile, nearly half of patients
presented with increased surgical risk (n = 1169/2745, 42.6%)
(logistic EuroSCORE 10%), when compared with 57.4% (1576 of
2745) of low risk (logistic EuroSCORE <10%).
Operative data and procedural outcomes
Isolated SURD-AVR was performed in 70.7% (2362 of 3340) of
patients through full sternotomy (704 of 1993, 35.3%) or less in-
vasive approaches (1289 of 1993, 64.7%). Of those who under-
went minimally invasive AVR (MIAVR) upper ministernotomy
was used in 55.4% (714 of 1288) and right anterior minithoracot-
omy in 44.6% (574 of 1288) of patients.
Concomitant procedures included CABG (712 of 3197, 22.3%),
mitral and/or tricuspid valve surgery (160 of 2784, 5.7%), septal
myectomy (67 of 2615, 2.6%), maze procedure (56 of 2730, 2.1%)
and ascending aorta or root surgery (53 of 2666, 2%). Mean CPB
and cross-clamp time were 87.3 ± 38.5 and 57.2 ± 28.7 min, re-
spectively. For isolated SURD-AVR, mean cross-clamp time was
47.5 ± 22.9 min for full sternotomy approach, 49.9 ± 17.1 min
for ministernotomy and 62.9 ± 23.1 min for minithoracotomy.
Among 3343 patients in the study cohort, Perceval S was im-
planted in 2461 (73.7%) patients, EDWARDS INTUITY or INTUITY
Elite in 757 (22.7%) patients and Enable 3F in 123 (3.7%) patients.
Devices implantation was successful in 98.9% of patients. Valve
migration/embolization and the intraoperative use of a different
prosthesis occurred in 0.8% and 0.9% of cases, respectively.
Prosthesis sizes and operative data are summarized in Tables 3
and 4, respectively.
Hospital outcomes
Overall hospital mortality was 2.1% (67 of 3222). It was 1.4% in
patients who had isolated SURD-AVR and 3.5% in those who had
concomitant procedures (P < 0.001). When considering the base-
line risk profile, mortality rate was 1.1% in low-risk patients (logis-
tic EuroSCORE <10%) when compared with 2.7% in patients at
increased surgical risk (logistic EuroSCORE >_10%) (Fig. 1).
Moreover, in very low-risk patients (logistic EuroSCORE <5%),
early mortality was 0.4% (n = 2 of 511) (Supplementary Material,
Fig. S2). The main postoperative complications included
bleeding requiring revision (97 of 2198, 4.4%), acute kidney injury
(>Stage 1) (78 of 2169, 3.6%), respiratory failure (111 of 3343,
3.3%) and neurological dysfunction (99 of 2636, 3.8%) involving
Table 1: Patient demographics
Frequency Percentage
Male 1371/3338 41.1
Age (n = 3336), mean ± SD 76.8 ± 6.7








BMI, mean ± SD 27.4 ± 4.8
COPD 475/2891 16.4
Renal insufficiency 561/3032 18.5
Cerebrovascular disease 325/2524 12.9
Atrial fibrillation 392/2396 16.4
Previous pacemaker implantation 135/3121 4.3
Bicuspid aortic valve 115/2020 5.7
Pulmonary hypertension 634/1921 33




Aortic valve stenosis 2233/3343 66.8
Aortic valve regurgitation 36/3343 1.1
Mixed aortic valve disease 1074/3343 32.1
Endocarditis 21/2680 0.8
Logistic EuroSCORE (%) (n = 2745),
mean ± SD
11.3 ± 9.7
AVR: aortic valve replacement; BMI: body mass index; CABG: coronary ar-
tery bypass grafting; COPD: chronic obstructive pulmonary disease; NYHA:
New York Heart Association; SD: standard deviation.
Table 2: Echocardiographic data
Frequency Percentage




Aortic valve area (cm2) (n = 1150),
median (IQR)
0.7 (0.6–0.8)
Peak aortic valve gradient (mmHg)
(n = 2105), mean ± SD
73.9 ± 31.3
Mean aortic valve gradient (mmHg)
(n = 2278), mean ± SD
46.3 ± 20.2
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stroke (75 of 2636, 2.8%) and transient ischaemic attack (24 of
2133, 1.1%) (Table 5). New atrioventricular block requiring pace-
maker (PM) occurred in 10.4% (281 of 2710) of patients (Perceval
10.7%, INTUITY 8.4% and Enable 3F 17.1%). As time passed, the
rate of PM implantation decreased from 17.2% to 5.4% (P = 0.02)
(Fig. 2). Significant postoperative aortic regurgitation was
observed in 26 of 1997 cases (1.3%), being moderate in 23 (1.2%)
and severe in 3 (0.2%) cases. Over the study period, the overall
aortic regurgitation rate (>_1+) significantly decreased from 17.2%
to 6% (P < 0.001) (Fig. 3). Postoperative mean peak valve gradient
was 25.3 ± 10.5 mmHg, and mean gradient was 13.3 ± 5.7 mmHg
(Table 3).
DISCUSSION
SURD-IR is the first international independent registry enrolling
patients undergoing SURD-AVR using any available sutureless
and rapid-deployment valve prosthesis at large referral centres. It
is currently the largest worldwide registry for sutureless and
rapid-deployment valves and represents a unique opportunity to
analyse contemporary data on the characteristics, haemo-
dynamic profiles and safety and efficacy outcomes of patients
undergoing SURD-AVR by minimizing the inherent biases
observed in small surgical registries or single-centre series.
The SURD-IR study cohort consisted of near octogenarians
(mean age 77 years, 36.4% of patients older than 80 years) with a
considerable burden of comorbidities that translated into a mean
logistic EuroSCORE of 11.3%, which was consistent with an
increased surgical risk [3]. Despite this high-risk profile, SURD-
AVR was associated with excellent operative and clinical out-
comes. Overall hospital mortality was 2.1%, being 1.4% and 3.5%
in patients undergoing isolated and combined SURD-AVR, re-
spectively. Our results compare favourably with those reported in
conventional AVR and TAVI registries both in low- and increased-
risk patients [4–6]. When stratified according to risk profile, early
Table 5: Postoperative morbidity
Frequency Percentage
Ventilatory support >72 h 111/3343 3.3
New onset atrial fibrillation 723/2648 27.3
New AV block requiring pacemaker 281/2710 10.4
Bleeding requiring revision 97/2198 4.4
Acute kidney injury (>Stage 1) 78/2169 3.6
Dialysis 33/1811 2.2
Neurological dysfunction 99/2636 3.8
Transient ischaemic attack 24/2133 1.1
Stroke 75/2636 2.8
Wound complications 49/1804 2.7
ICU stay (days) (n = 2235), median (IQR) 1 (1–3)
Hospital stay (days) (n = 2818),
median (IQR)
9 (7–14)
AV: atrioventricular; ICU: intensive care unit; IQR: interquartile range.
Table 3: Valve prostheses: sizes and postoperative haemo-
dynamics






Perceval S 2461/3341 (73.7) 26.4 ± 10.5 14.1 ± 5.8
Small 317/2356 (13.5) 28.4 ± 10.3 15.1 ± 5.9
Medium 876/2356 (37.2) 27.6 ± 10.9 15 ± 6.1
Large 906/2356 (38.5) 25.5 ± 10.2 13.4 ± 5.4
Extra large 257/2356 (10.9) 23.5 ± 10.2 12.2 ± 5.3
EDWARS INTUITY/
INTUITY Elite
757/3341 (22.7) 21.9 ± 8.7 11.3 ± 4.9
19 74/748 (9.9) 34.3 ± 10.1 17.2 ± 5.2
21 210/748 (28.1) 22.7 ± 7 11.8 ± 4
23 242/748 (32.4) 20.9 ± 7.4 11 ± 4.9
25 163/748 (21.8) 19.6 ± 8.7 9.8 ± 4.4
27 59/748 (7.9) 17 ± 6.7 8.3 ± 3.4
SD: standard deviation.
Figure 1: In-hospital mortality according to patient risk profile. logES: logistic
EuroSCORE; pts: patients; SURD-AVR: sutureless and rapid-deployment aortic
valves replacement.
Table 4: Operative data
Frequency Percentage
Isolated SURD-AVR 2362/3340 70.7
Full sternotomy 704/1993 35.3
Ministernotomy 714/1991 35.9
Minithoracotomy 574/1991 28.9
Concomitant procedures 978/3340 29.3
CABG 712/3197 22.3
Valve surgery (mitral/tricuspid) 160/2784 5.7
Septal myectomy 67/2615 2.6
Maze procedure 56/2730 2.1
Thoracic aorta surgery 53/2666 2
Valve type
Perceval S 2461/3341 73.7
Intuity 757/3341 22.7
Enable 3F 123/3341 3.7
CPB time (min) (n = 3212),
mean ± SD
87.3 ± 38.5
Aortic cross-clamp time (min)
(n = 3218), mean ± SD
57.2 ± 28.7
Isolated AVR full sternotomy 47.5 ± 22.9
Isolated AVR ministernotomy 49.9 ± 17.1
Isolated AVR minithoracotomy 62.9 ± 23.1
Combined AVR 75.6 ± 37.5
AVR: aortic valve replacement; CABG: coronary artery bypass grafting; CPB:
cardiopulmonary bypass; SD: standard deviation; SURD-AVR: sutureless
and rapid-deployment aortic valve replacement.
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mortality was 0.8% and 1.9% in low risk (logistic EuroSCORE <10%)
isolated SURD-AVR and combined SURD-AVR and 2.2% and 3.7%
in increased risk patients (logistic EuroSCORE >_10%), respectively.
Moreover, in very low-risk patients (logistic EuroSCORE <5%), the
mortality rate was outstandingly low (0.4%). In this setting, the
German Aortic Valve Registry (GARY) showed comparable 30-day
mortality in low-risk patients undergoing isolated (1.5%) or com-
bined AVR (2.7%) [4]. However, reported early mortality was con-
siderably higher in low-risk TAVI patients (3.7%) and in patients at
increased risk (logistic EuroSCORE 10–20%) undergoing isolated
AVR (3.7%), combined AVR (5.1%) and TAVI (4.1%) [4].
During heart valve surgery, prolonged CPB and cross-clamp
times are strong predictors for early mortality and major postoper-
ative complications. This harmful effect further increases when sur-
gery is performed in elderly or high-risk patients [7]. Sutureless and
rapid-deployment prostheses, which do not require placement
and tying of sutures, have been associated with considerably
reduced procedural times and improved surgical outcomes [8–13].
In SURD-IR, CPB and cross-clamp times were significantly shorter
than those reported in the Society of Thoracic Surgeons (STS)
database, both in overall isolated AVR (79 and 51 min vs. 106 and
78 min) and combined AVR + CABG (106 and 72 min vs 147 and
112 min).
Because of the simplified handling and the quicker deploy-
ment, SURD-AVR remarkably facilitates minimally invasive
approaches [10]. This finding is confirmed by the observation
possible with the present registry, with almost two-thirds of
isolated AVRs performed through a less invasive approach. As re-
ported by others [11, 12, 14], the high rate of minimally invasive
approaches did not significantly impact the overall CPB and
cross-clamp times, which were 80 and 50 min, for ministernot-
omy and 97 and 64 min for minithoracotomy, respectively.
SURD-AVR has been associated with better haemodynamic per-
formances when compared with conventional valves [12, 14–20]. In
SURD-IR, the mean and peak valve gradients were 13 and
25 mmHg, respectively. These gradients may still appear a bit higher
than expected, but this has to do with the predominantly small to
medium-sized annular diameter (19–23 mm) of our patients.
Concern exists regarding the increased incidence of conduc-
tion disorders following SURD-AVR [14, 21, 22]. In the population
of the registry, the overall PM implantation rate was 10.4%. This
may be related in part to the high-risk profile of the patients and
with subclinical preoperative conduction disorders [23, 24].
Unfortunately, data on preoperative conduction abnormalities
collected in the registry were insufficient, precluding adequately
powered conclusions. In addition, the threshold for postoperative
PM implantation may have been different between the centres.
However, it has been suggested that the principal cause may be
the ‘learning curve effect’ in terms of procedural implanting steps
and mainly sizing. In this setting, several authors have proposed
simple technical modifications of valve implantation technique
to prevent conduction disorders [25, 26]. In the SURD-IR study
cohort, indeed, the rate of PM implantation diminished signifi-
cantly over the study period, from 17.2% to 5.4% (P = 0.002),
(Fig. 2). This compares satisfactorily with the rates reported for
sutured AVR and TAVI [27]. Finally, the ‘learning curve effect’ sig-
nificantly influenced the incidence of aortic regurgitation as well.
Indeed, the rate and the severity of postoperative aortic insuffi-
ciency decreased significantly over time (Fig. 3).
Limitations
This study has limitations of any observational registry involving no
adjudication of patient inclusion and data collection and the lack of
comparative arms, which does not allow powerful conclusions on
the risk–benefit regarding the different prostheses used and the sur-
gical approaches. Because of the retrospective nature of the registry,
no VARC II criteria [28] were used for events adjudication.
Moreover, there is no core laboratory to review images yet, and
the investigators are responsible for data reporting from their own
institutions. However, the SURD-IR is the largest and the only
Figure 3: Aortic regurgitation rate over the study period. PTS: patients.
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independent SURD-AVR registry, including all available sutureless
and rapid-deployment valves. Thus, it reflects a ‘real-world’ scenario
and gives a valuable opportunity to assess this new technology.
CONCLUSIONS
With more than 3300 patients enrolled, the SURD-AVR
International Registry is currently the largest worldwide registry
on sutureless, rapid-deployment aortic valves that provides a
real-world picture of SURD-AVR surgery. This article confirms
that SURD-AVR is a safe and efficacious alternative to conven-
tional AVR with excellent clinical outcomes. SURD-AVR may have
the potential to become the new gold standard treatment for
aortic valve surgery: when compared with conventional AVR,
SURD-AVR may facilitate less invasive approaches, allow shorter
operative times and provide satisfactory haemodynamic results.
We believe that more powered statistical analyses will give more
and better evidence with this type of prostheses and may help to
find a place for SURD-AVR in the valvular guidelines.
SUPPLEMENTARY MATERIAL
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